ArticleCancers2019
High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03158571 (Chilean Gastric Cancer Task Force), which is not on this map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chilean Gastric Cancer Task Force (FORCE 1): A Study Protocol to Obtain a Clinical and Molecular Classification of a Cohort of Gastric Cancer Patients.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Comprehensive histopathological analysis of gastric cancer in European and Latin America populations reveals differences in PDL1, HER2, p53 and MUC6 expression.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- A snapshot of cancer in Chile II: an update on research, strategies and analytical frameworks for equity, innovation and national development.Biological research · 2024Article
- Differentially Expressed Genes and Signaling Pathways Potentially Involved in Primary Resistance to Chemo-Immunotherapy in Advanced-Stage Gastric Cancer Patients.International journal of molecular sciences · 2022Article
- Mutational landscape of gastric adenocarcinoma in Latin America: A genetic approach for precision medicine.Genes & diseases · 2022Review
- Characterization of Tumor Mutation Burden-Based Gene Signature and Molecular Subtypes to Assist Precision Treatment in Gastric Cancer.BioMed research international · 2022Article
- Efficacy and Safety of Camrelizumab in Combination with Docetaxel + S-1 Sequenced by Camrelizumab + S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial.Frontiers in surgery · 2022Article
- Observational
- Recent advances in immune therapies for gastric cancer.Cancer gene therapy · 2021Review
- Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions.Genome biology · 2021Article
- The Reprimo-Like Gene Is an Epigenetic-Mediated Tumor Suppressor and a Candidate Biomarker for the Non-Invasive Detection of Gastric Cancer.International journal of molecular sciences · 2020Article
- Gastric cancer: a comprehensive review of current and future treatment strategies.Cancer metastasis reviews · 2020Review
- A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability.Cancers · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 3 institutions in 2 countries.
Miguel Cordova-DelgadoHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.ORCID 0000-0002-3132-226X
Mauricio P PintoHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.ORCID 0000-0003-2484-8033
Ignacio N RetamalHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.ORCID 0000-0003-4633-2556
Matías Muñoz-MedelHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
María Loreto BravoHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
María F FernándezHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
Betzabé CisternasHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
Sebastián MondacaHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
César SanchezHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
Hector GalindoHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.ORCID 0000-0001-5741-2266
Bruno NerviHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
Carolina IbáñezHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
Francisco AcevedoHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
Jorge MadridHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
José PeñaHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
Erica KochHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
Maria José MaturanaHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.ORCID 0000-0003-4665-9583
Diego RomeroDepartment of Pathology, Faculty of Medicine, PUC, Santiago 8330023, Chile.
Nathaly de la JaraDepartment of Pathology, Faculty of Medicine, PUC, Santiago 8330023, Chile.
Javiera TorresDepartment of Pathology, Faculty of Medicine, PUC, Santiago 8330023, Chile.
Manuel EspinozaCentre of Clinical Research, Health Technology Assessment Unit, PUC, Santiago 8330032, Chile.
Carlos BalmacedaCentre of Clinical Research, Health Technology Assessment Unit, PUC, Santiago 8330032, Chile.
Yuwei LiaoCenter of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, Liaoning, China.
Zhiguang LiCenter of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, Liaoning, China.ORCID 0000-0003-2474-3485
Matías FreireCenter of Excellence in Precision Medicine (CEMP), Obispo Espinoza Campos 2526, Macul, Santiago 7810305, Chile.
Valentina Gárate-CalderónCenter of Excellence in Precision Medicine (CEMP), Obispo Espinoza Campos 2526, Macul, Santiago 7810305, Chile.
Javier CáceresCenter of Excellence in Precision Medicine (CEMP), Obispo Espinoza Campos 2526, Macul, Santiago 7810305, Chile.
Gonzalo Sepúlveda-HermosillaCenter of Excellence in Precision Medicine (CEMP), Obispo Espinoza Campos 2526, Macul, Santiago 7810305, Chile.
Rodrigo LizanaCenter of Excellence in Precision Medicine (CEMP), Obispo Espinoza Campos 2526, Macul, Santiago 7810305, Chile.
Liliana RamosCenter of Excellence in Precision Medicine (CEMP), Obispo Espinoza Campos 2526, Macul, Santiago 7810305, Chile.
Rocío ArtigasAdvanced Center for Chronic Diseases (ACCDiS), Core Biodata, Santiago 8330034, Chile.
Enrique NoreroDepartment of Gastrointestinal Surgery, PUC, Santiago 8330024, Chile.ORCID 0000-0002-6262-4930
Fernando CrovariDepartment of Gastrointestinal Surgery, PUC, Santiago 8330024, Chile.
Ricardo ArmisénCenter of Excellence in Precision Medicine (CEMP), Obispo Espinoza Campos 2526, Macul, Santiago 7810305, Chile.ORCID 0000-0003-2567-0521
Alejandro H CorvalánHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.
Gareth I OwenHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile.ORCID 0000-0003-3807-6054
Marcelo GarridoHematology & Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago 8330032, Chile. mgarrido@med.puc.cl.
Pontificia Universidad Católica de Chile · CLDalian Medical University · CNAdvanced Center for Chronic Diseases · CL
Funding
Comisión Nacional de Investigación Científica y Tecnológica 21150695Fondo Nacional de Desarrollo Científico y Tecnológico 1180173Fondo Nacional de Desarrollo Científico y Tecnológico 1180241Fondo Nacional de Desarrollo Científico y Tecnológico 1191928National Natural Science Foundation of China 81472637National Natural Science Foundation of China 81672784National Natural Science Foundation of China 81872655
Abstract
Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA;
Indexed as
cancer subtypesgastric adenocarcinomagastric cancermolecularprognosissurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT03158571ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.